03.11.15
Medtronic plc has acquired Advanced Uro-Solutions, a privately held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tenn.
Neuromodulation involves the targeted and regulated delivery of electrical pulses and pharmaceuticals to specific sites in the nervous system.
Terms of the agreement, which closed in December, were not disclosed.
Advanced Uro-Solutions develops and manufactures the Nuro percutaneous tibial nerve stimulation system, which consists of a small external stimulator and a single, reusable lead to provide temporary stimulation to the tibial nerve. This therapy is 510(k) cleared by the U.S. Food and Drug Administration (FDA) to treat patients with overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Medtronic is preparing to launch the Nuro system in the United States within the next 12 months.
More than 37 million adults in the United States—one in six—suffer from OAB, according to figures cited by Medtronic. By 2018, it is estimated that 546 million people worldwide will be affected by OAB.
With this deal, the company will be competing with Minnetonka, Minn.-based Uroplasty Inc., which also makes a neuromodulation device—Urgent PC—to treat OAB.
Both companies’ devices are similar. Advanced Uro-Solutions’ technology was cleared by the FDA toward the end of 2013 by proving that its device is substantially equivalent to Uroplasty’s.
“The acquisition of Advanced Uro-Solutions expands Medtronic’s portfolio of treatment options for those suffering from chronic symptoms of overactive bladder,” said Linnea Burman, vice president and general manager, gastro/urology therapies at Medtronic.
“Medtronic continues to invest in fully implantable bladder control and bowel control therapies, and the addition of the Nuro system to our existing portfolio of products will introduce more people suffering from bladder control issues to the benefits of neuromodulation.”
Since 2009, Advanced Uro-Solutions has been led by two founders, Brent Laing and John Green.
“Studies show that roughly 80 percent of patients prescribed oral medications to treat their OAB symptoms have stopped taking them at 12 months, and Medtronic shares our commitment to advancing neuromodulation and increasing patient access to advanced solutions intended to treat their symptoms,” said Green, former chairman and CEO of Advanced Uro-Solutions. “We are excited to take this step toward making this important therapy available to patients around the world.”
Medtronic’s Neuromodulation division includes implantable neurostimulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity and urologic and gastrointestinal disorders.
Medtronic will include revenue from the Advanced Uro-Solutions product line as part of the Neuromodulation division within the Restorative Therapies Group.
Medtronic is based in Dublin, Ireland.
Neuromodulation involves the targeted and regulated delivery of electrical pulses and pharmaceuticals to specific sites in the nervous system.
Terms of the agreement, which closed in December, were not disclosed.
Advanced Uro-Solutions develops and manufactures the Nuro percutaneous tibial nerve stimulation system, which consists of a small external stimulator and a single, reusable lead to provide temporary stimulation to the tibial nerve. This therapy is 510(k) cleared by the U.S. Food and Drug Administration (FDA) to treat patients with overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Medtronic is preparing to launch the Nuro system in the United States within the next 12 months.
More than 37 million adults in the United States—one in six—suffer from OAB, according to figures cited by Medtronic. By 2018, it is estimated that 546 million people worldwide will be affected by OAB.
With this deal, the company will be competing with Minnetonka, Minn.-based Uroplasty Inc., which also makes a neuromodulation device—Urgent PC—to treat OAB.
Both companies’ devices are similar. Advanced Uro-Solutions’ technology was cleared by the FDA toward the end of 2013 by proving that its device is substantially equivalent to Uroplasty’s.
“The acquisition of Advanced Uro-Solutions expands Medtronic’s portfolio of treatment options for those suffering from chronic symptoms of overactive bladder,” said Linnea Burman, vice president and general manager, gastro/urology therapies at Medtronic.
“Medtronic continues to invest in fully implantable bladder control and bowel control therapies, and the addition of the Nuro system to our existing portfolio of products will introduce more people suffering from bladder control issues to the benefits of neuromodulation.”
Since 2009, Advanced Uro-Solutions has been led by two founders, Brent Laing and John Green.
“Studies show that roughly 80 percent of patients prescribed oral medications to treat their OAB symptoms have stopped taking them at 12 months, and Medtronic shares our commitment to advancing neuromodulation and increasing patient access to advanced solutions intended to treat their symptoms,” said Green, former chairman and CEO of Advanced Uro-Solutions. “We are excited to take this step toward making this important therapy available to patients around the world.”
Medtronic’s Neuromodulation division includes implantable neurostimulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity and urologic and gastrointestinal disorders.
Medtronic will include revenue from the Advanced Uro-Solutions product line as part of the Neuromodulation division within the Restorative Therapies Group.
Medtronic is based in Dublin, Ireland.